Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma

被引:8
作者
Agackiran, Yetkin [1 ]
Aksu, Funda [2 ]
Akyurek, Nalan [3 ]
Ercan, Caner [4 ]
Demiroz, Mustafa [2 ]
Aksu, Kurtulus [5 ]
机构
[1] Hlth Sci Univ, Dept Pathol, Ataturk Chest Dis & Chest Surg Educ & Res Hosp, Ankara, Turkey
[2] Hlth Sci Univ, Dept Chest Dis, Ataturk Chest Dis & Chest Surg Educ & Res Hosp, Ankara, Turkey
[3] Gazi Univ, Dept Pathol, Sch Med, Ankara, Turkey
[4] Univ Hosp Basel, Instute Pathol, Basel, Switzerland
[5] Hlth Sci Univ, Dept Chest Dis, Div Immunol & Allergy, Ataturk Chest Dis & Chest Surg Educ & Res Hosp, Ankara, Turkey
关键词
carcinoma; carcinosarcoma; giant cell; survival analysis; PULMONARY PLEOMORPHIC CARCINOMA; SHOW HIGH-LEVELS; PLEURAL INVASION; PD-L1; EXPRESSION; CANCER; CLASSIFICATION; BLOCKADE;
D O I
10.1111/ajco.13460
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim To determine the programmed death ligand-1 (PD-L1) expression rates in sarcomatoid lung carcinomas and to compare clinicopathologic features and survival rates of PD-L1-positive and negative patients. Methods PD-L1 expression was evaluated in 65 surgically resected sarcomatoid carcinomas. The clinicopathologic features of cases with PD-L1-positive and negative tumors were compared. Kaplan-Meier survival analysis was performed. Multiple Cox proportional hazard regression analysis was performed to determine independent predictors of overall survival. Results PD-L1 antibody positivity was found in 72.3% of surgically resected sarcomatoid lung carcinomas. Regarding histopathologic subtypes, PD-L1 expression was positive in 80.4% of pleomorphic carcinomas, 62.5% of spindle- and/or giant-cell carcinomas, and 16.7% of carcinosarcomas. Pleural invasion was observed in 68.1% of PD-L1-positive cases and 27.8% of PD-L1-negative cases (P = 0.008). No difference in survival was found between PD-L1-positive and -negative tumors. The only factor significantly associated with poor survival was the pathological stage of the tumor. Conclusions This study reveals a high rate of PD-L1 positivity in a large number of sarcomatoid lung carcinoma cases with pleomorphic carcinoma, spindle- and/or giant-cell carcinoma, and carcinosarcoma subtypes. The only significantly different clinicopathologic feature in PD-L1-positive cases is pleural invasion. PD-L1 positivity is not a significant predictor of survival in sarcomatoid lung carcinomas.
引用
收藏
页码:280 / 288
页数:9
相关论文
共 37 条
[1]   Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer [J].
Adam, J. ;
Le Stang, N. ;
Rouquette, I. ;
Cazes, A. ;
Badoual, C. ;
Pinot-Roussel, H. ;
Tixier, L. ;
Danel, C. ;
Damiola, F. ;
Damotte, D. ;
Penault-Llorca, F. ;
Lantuejoul, S. .
ANNALS OF ONCOLOGY, 2018, 29 (04) :953-958
[2]   PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami ;
Tatiparti, Katyayani ;
Bhise, Ketki ;
Kashaw, Sushil K. ;
Iyer, Arun K. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[3]  
Babacan NA, 2020, CLIN LUNG CANCER, VS1525-7304, P30073
[4]   Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm [J].
Berghmans, Thierry ;
Dingemans, Anne-Marie ;
Hendriks, Lizza E. L. ;
Cadranel, Jacques .
EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (02)
[5]   High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma [J].
Chang, Yih-Leong ;
Yang, Ching-Yao ;
Lin, Mong-Wei ;
Wu, Chen-Tu ;
Yang, Pan-Chyr .
EUROPEAN JOURNAL OF CANCER, 2016, 60 :125-135
[6]  
FISHBACK NF, 1994, CANCER-AM CANCER SOC, V73, P2936, DOI 10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO
[7]  
2-U
[8]  
Goldstraw P., 2009, INT ASS STUDY LUNG C
[9]   Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy [J].
Hamid, Omid ;
Carvajal, Richard D. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) :847-861
[10]   PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project [J].
Hirsch, Fred R. ;
McElhinny, Abigail ;
Stanforth, Dave ;
Ranger-Moore, James ;
Jansson, Malinka ;
Kulangara, Karina ;
Richardson, William ;
Towne, Penny ;
Hanks, Debra ;
Vennapusa, Bharathi ;
Mistry, Amita ;
Kalamegham, Rasika ;
Averbuch, Steve ;
Novotny, James ;
Rubin, Eric ;
Emancipator, Kenneth ;
McCaffery, Ian ;
Williams, J. Andrew ;
Walker, Jill ;
Longshore, John ;
Tsao, Ming Sound ;
Kerr, Keith M. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :208-222